Furthermore, HME was proved as a blocker for STAT3 activation, evidenced by the findings that HME inhibits both constitutive and IL-6-induced activation of STAT3, and STAT3 blockage is needed for HME to suppress the viability and clonogenicity of bladder cancer cells (Figure 3). This evidence concerns the gene IL6 and urinary bladder carcinoma.